DexCom Investor Suits Intensify as Firms Set Competing Lead-Plaintiff Deadlines
Plaintiffs frame the dispute around unapproved sensor changes that allegedly degraded device accuracy.
Overview
- Levi & Korsinsky and Bragar Eagel & Squire highlight a December 26, 2025 deadline for investors to seek lead-plaintiff status.
- Rosen Law Firm sets a separate December 29, 2025 deadline tied to a class period from July 26, 2024 through September 17, 2025.
- Other notices define the class period as January 8, 2024 through September 17, 2025, creating overlapping eligibility windows.
- The complaints allege DexCom made material G6 and G7 design changes without FDA authorization that reduced reliability and posed health risks.
- Filings state the company overstated G7 performance and minimized risks, and they note no class has been certified and investors may choose their own counsel.